J1826 Interferon Beta-1a | HCPCS Reimbursement | OpenPayer

Summary & Overview

HCPCS J1826: Injection, interferon beta-1a, 30 mcg

HCPCS Level II code J1826 denotes a 30 mcg injection of interferon beta-1a, a parenteral disease-modifying therapy used in neurology. Nationally, this code is important for accurate reporting of administered biologic agents, tracking utilization of injectable therapies, and aligning billing with clinical administration in outpatient settings. Payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what J1826 represents, who reimburses these administrations, and the clinical context for use. The publication presents benchmarking and reimbursement-related context, common billing considerations, and recent policy updates that affect coverage and claims processing. It also outlines typical service settings where the injection is administered and highlights areas where providers commonly encounter coding or billing questions.

The content is intended for billing managers, practice administrators, and policy analysts seeking a national-level briefing on coding and administrative considerations for interferon beta-1a 30 mcg injections. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ1826HCPCS Level IIinterferon beta-1ainjectiondrug administrationoutpatient infusionneurologybillingreimbursement

Billing Code Overview

HCPCS Level II code J1826 represents an injection of interferon beta-1a, 30 mcg. This code describes a parenteral disease-modifying therapy administered for conditions treated with interferon beta-1a.

Service type: Injection/Drug Administration

Typical site of service: Outpatient clinic, physician office, or infusion center

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 28–55-year-old individual diagnosed with relapsing-remitting multiple sclerosis who receives disease-modifying therapy with interferon beta-1a. The patient presents to an outpatient infusion clinic or an ambulatory injection suite for administration of J1826 (injection, interferon beta-1a, 30 mcg). The clinical workflow includes verification of identity and insurance, review of recent laboratory results (for hepatic function and complete blood count), screening for contraindications or intercurrent infection, and assessment of prior injection tolerance and adverse effects. The medication is prepared under aseptic technique by pharmacy or nursing staff, the injection site (usually subcutaneous or intramuscular per product instructions) is inspected and cleaned, and the dose is administered. Post-injection observation for acute hypersensitivity or flu-like symptoms occurs for a short period (typically 15–30 minutes) with documentation of lot number, dose, route, site, and patient response. Billing uses HCPCS J1826 for the drug; potential coordination with facility charges or administration CPT codes occurs depending on site of service (outpatient hospital infusion center, physician office, or ambulatory infusion suite).

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier, standard reporting

HCPCS J2919: Methylprednisolone Sodium Succinate Injection, 5 mg

HCPCS-J2180-MEPERIDINE-PROMETHAZINE-INJECTION-UP-TO-50-MG

HCPCS J2180: Injection, Meperidine and Promethazine HCl, up to 50 mg

HCPCS-J0896-LUSPATERCEPT-INJECTION-025-MG

HCPCS J0896: Luspatercept-aamt Injection, 0.25 mg

HCPCS-J2359-OLANZAPINE-INJECTION-05-MG

HCPCS J2359: Injection, olanzapine 0.5 mg

HCPCS-J7506-PREDNISONE-ORAL-5MG

HCPCS Level II J7506: Prednisone, Oral, per 5 mg

HCPCS-J1951-LEUPROLIDE-ACETATE-DEPOT-0-25-MG

HCPCS J1951: Leuprolide Acetate Depot Injection, 0.25 mg

HCPCS-J2670-TOLAZOLINE-INJECTION-25MG

HCPCS J2670: Tolazoline HCl Injection, up to 25 mg

HCPCS-J7169-ANDEXXA-10MG-FACTOR-XA-REVERSAL-INJECTION

HCPCS J7169: Andexxa (Coagulation Factor Xa Recombinant) 10 mg Injection

HCPCS-J0210-METHYLDOPATE-INJECTION-250MG

HCPCS J0210: Injection, Methyldopate HCl, up to 250 mg

HCPCS-J1438-ETANERCEPT-25MG-INJECTION-PHYSICIAN-ADMINISTERED

HCPCS Level II J1438: Etanercept 25 mg Injection, Physician-Administered

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`207RH0000X`	Neurology	Neurologists commonly prescribe and oversee interferon beta-1a therapy for multiple sclerosis.
`363LF0000X`	Family Medicine	Primary care physicians may administer or coordinate ongoing injections and monitoring.
`164W00000X`	Physician Assistant	PAs often perform injections and follow-up management in outpatient clinics.
`163W00000X`	Nurse Practitioner	NPs frequently administer injections and manage therapy in ambulatory settings.
`164N00000X`	Registered Nurse	RNs in infusion or injection clinics perform preparation, administration, and monitoring.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G35`	Multiple sclerosis	Primary indication for interferon beta-1a therapy; used to reduce relapse frequency and delay disability progression.
`G36.0`	Neuromyelitis optica	Some demyelinating disorders may be considered in differential diagnosis; therapy selection differs but may involve neurologic disease-modifying agents.
`D61.9`	Aplastic anemia, unspecified	Relevant as a cautionary condition — hematologic monitoring is required during interferon therapy.
`E83.109`	Disorder of phosphorus metabolism, unspecified	Metabolic disorders may alter therapy tolerance; included as an example of comorbidity that affects monitoring.
`Z79.899`	Other long term (current) drug therapy	Used to denote long-term use of disease-modifying therapy when documenting chronic interferon administration.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly used to report the actual administration of subcutaneous or intramuscular `J1826` when separate administration coding is required in an office or clinic setting.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Occasionally used in oncology admin contexts; not typical for interferon beta-1a but included when facility-specific protocols require chemotherapy series coding.
`99070`	Supplies and materials (except spectacles), used for patient care, not included in service	Used to bill for additional disposable supplies required for injection preparation and administration when payor allows.
`99072`	Additional supplies, personal protective equipment (PPE) during public health emergency	Used when PPE supply charges are billable per payor policy during designated periods.
`36415`	Collection of venous blood by venipuncture	Used when pre-administration labs (e.g., liver function tests, CBC) are obtained at the visit prior to `J1826` administration.

OpenPayer